Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias

Oncotarget

Volumn 2, Issue 12, 2011, Pages 1043-1054

  Schneckenleithner, Christine ^a   Bago Horvath, Zsuzsanna ^b   Dolznig, Helmut ^b   Neugebauer, Nina ^a   Kollmann, Karoline ^a   Kolbe, Thomas ^a   Decker, Thomas ^c   Kerjaschki, Dontscho ^b   Wagner, Kay Uwe ^d   Müller, Mathias ^a   Stoiber, Dagmar ^b,e   Sexl, Veronika ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

IRF1; Mammary cancer; MIN; Stat1; Tumorsurveillance

Indexed keywords

INTERFERON REGULATORY FACTOR 1; IRF1 PROTEIN, MOUSE; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE;

ACINAR CELL; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CARCINOMA IN SITU; CELL PROLIFERATION; CELL TRANSFORMATION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; EPITHELIUM CELL; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; NATURAL KILLER CELL; PATHOLOGY; SIGNAL TRANSDUCTION; UDDER;

ACINAR CELLS; ANIMALS; CARCINOMA IN SITU; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; FEMALE; INTERFERON REGULATORY FACTOR-1; KILLER CELLS, NATURAL; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84862980088     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.371     Document Type: Article

References (36)

1. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature reviews. 2009; 9:798-809.
2. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Current opinion in oncology. 1999; 11:490-496.
3. Watson CJ, Neoh K. The Stat family of transcription factors have diverse roles in mammary gland development. Semin Cell Dev Biol. 2008; 19:401-406.
4. Philp JA, Burdon TG, Watson CJ. Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett. 1996; 396:77-80.
5. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W. Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res. 2002; 8:3065-3074.
6. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010; 12:R85.
7. Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG, Boland MP. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 2004; 64:8357-8364.
8. Yang PY, Chen MF, Kao YH, Hu DN, Chang FR, Wu YC. Norcantharidin induces apoptosis of breast cancer cells: Involvement of activities of mitogen activated protein kinases and signal transducers and activators of transcription. Toxicol In Vitro. 2011.
9. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L. Loss of STAT1 from mouse mammary epithelium results in an increased neu-induced tumor burden. Neoplasia. 2010; 12:899-905.
10. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, Koromilas AE. Stat1 is a suppressor of ErbB2/ Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle. 2011; 10:794-804
11. Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, Medina D, Jerry DJ, Blackburn AC, Peltz G, Amos CI, Lozano G. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome. 2007; 18:300-309.
12. Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004; 279:5811-5820.
13. Lee CK, Smith E, Gimeno R, Gertner R, Levy DE. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma. J Immunol. 2000; 164:1286-1292.
14. Stephanou A, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight RA, Latchman DS. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem. 2001; 276:28340-28347.
15. Kim HS, Lee MS. STAT1 as a key modulator of cell death. Cellular signalling. 2007; 19:454-465.
16. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996; 84:443-450.
17. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois RN, Clark R, Aguet M, Schreiber RD. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996; 84:431-442.
18. Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, Stoiber D, Sexl V, Kolbe T, Rulicke T, Muller M, Decker T. Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL. J Immunol. 2009; 183:2286-2293.
19. Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol. 2000; 165:3571-3577.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19:403-410.
21. Doherty GM, Boucher L, Sorenson K, Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg. 2001; 233:623-629.
22. Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat. 2009; 121:227-231.
23. Kim PK, Armstrong M, Liu Y, Yan P, Bucher B, Zuckerbraun BS, Gambotto A, Billiar TR, Yim JH. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene. 2004; 23:1125-1135.
24. Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis. 2005; 26:1527-1535.
25. Jechlinger M, Podsypanina K, Varmus H. Regulation of transgenes in three-dimensional cultures of primary mouse mammary cells demonstrates oncogene dependence and identifies cells that survive deinduction. Genes Dev. 2009; 23:1677-1688.
26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410:1107-1111.
27. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. International journal of cancer. 2009; 124:2124-2134.
28. Ward PL, Schreiber H. MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors. Seminars in cancer biology. 1991; 2:321- 328.
29. Philipps C, Stauss HJ, Wortzel RD, Schreiber H. A novel MHC class I molecule as a tumour-specific antigen. Correlation between the antibody-defined and the CTL-defined target structure. Journal of immunogenetics. 1986; 13:93-99.
30. Kirchhoff S, Schaper F, Hauser H. Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes. Nucleic Acids Res. 1993; 21:2881-2889.
31. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res. 2002; 22:39- 47.
32. Taniguchi T, Harada H, Lamphier M. Regulation of the interferon system and cell growth by the IRF transcription factors. Journal of cancer research and clinical oncology. 1995; 121:516-520.
33. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010; 102:170-178.
34. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A, et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell. 1993; 75:83-97.
35. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992; 68:855-867.
36. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-Holzner E, Lax SF, Obrist P, Rudas M, Quehenberger F. Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Arch. 2002; 441:328-334.